Samira Saady Morhy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samira Saady Morhy has a total of 252 co-authors. Here are the top co-authors by number of shared publications:
- Ana Clara Tude Rodrigues
Hospital Israelita Albert Einstein, Brasil; Universidade de São Paulo, Brasil
8 shared publications - Marcelo Luiz Campos Vieira
Heart Institute (Incor), São Paulo University Medical School, São Paulo, Brazil, Brazil
8 shared publications - Silvio Henrique Barberato
Pontifícia Universidade Católica do Paraná, Brasil
8 shared publications - Claudio Henrique Fischer
Universidade Federal de São Paulo
7 shared publications - Edgar Lira-Filho
Einstein Hospital Istaelita
6 shared publications - Adenalva Lima de Souza Beck
Instituto de Cardiologia e Transplantes do Distrito Federal, Brasil; Hospital Sirio Libanês, Brasil
5 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 24
Biventricular endomyocardial fibrosis with right ventricular hypertrabeculation and rapid progression to heart transplantation: imaging and pathologic correlation
- 2 September 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 24
Open AccessBiventricular endomyocardial fibrosis with right ventricular hypertrabeculation and rapid progression to heart transplantation: imaging and pathologic correlation
- Open Access
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e042405
Elevated Interleukin‐6 Levels in Socioeconomically Disadvantaged Children With Borderline Subclinical Rheumatic Heart Disease in São Paulo, Brazil: A Prospective Cohort Study Highlighting Early Detection and Treatment Opportunities
Background: Subclinical rheumatic heart disease (SCRHD) is the precursor to symptomatic disease, yet the cytokine profile of its earliest borderline stage remains uncharacterized. It is unknown whether inflammatory markers persist longitudinally in subclinical rheumatic heart disease. This study characterized the cytokine profile in borderline SCRHD at baseline and evaluated its longitudinal evolution over a 2‐year period in the combined SCRHD (borderline and definitive). Methods: In a prospective cohort study, 1026 children (5–15 years) from disadvantaged areas of São Paulo, Brazil, underwent echocardiographic screening. Participants were classified as normal, borderline SCRHD, or definite SCRHD according to World Health Organization criteria. Plasma levels of interleukin‐6 (IL‐6), tumor necrosis factor‐alpha, and other cytokines were measured at baseline (T0) and after 2 years (T1). Results: The prevalence of SCRHD was 7.6% (95% CI, 6.0%–9.2%), with 6.7% borderline (95% CI, 5.2%–8.2%) and 0.9% as definite (95% CI, 0.3%–1.5%). At baseline, IL‐6 levels were significantly higher in the borderline SCRHD group compared with controls ( P =0.048), while tumor necrosis factor‐alpha showed a trend toward elevation ( P =0.067). No significant differences were observed for interleukin‐2 ( P =0.067), interleukin‐4 ( P =1.000), interleukin‐10 ( P =0.690), interleukin‐17A ( P =0.067), or interferon‐gamma ( P =0.456). Among 44 participants followed for 2 years, IL‐6 and tumor necrosis factor‐alpha levels remained persistently elevated, with no significant change over time ( P =0.626 and P =0.144, respectively), indicating ongoing inflammatory activity. Conclusions: Borderline SCRHD is marked by elevated IL‐6 levels that last for at least 2 years, indicating a sustained proinflammatory state from the earliest detectable stage of the disease. These findings identify interleukin‐6 as a potential early biomarker and therapeutic target to prevent the progression of SCRHD.
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e042405
Open AccessElevated Interleukin‐6 Levels in Socioeconomically Disadvantaged Children With Borderline Subclinical Rheumatic Heart Disease in São Paulo, Brazil: A Prospective Cohort Study Highlighting Early Detection and Treatment Opportunities
Background: Subclinical rheumatic heart disease (SCRHD) is the precursor to symptomatic disease, yet the cytokine profile of its earliest borderline stage remains uncharacterized. It is unknown whether inflammatory markers persist longitudinally in subclinical rheumatic heart disease. This study characterized the cytokine profile in borderline SCRHD at baseline and evaluated its longitudinal evolution over a 2‐year period in the combined SCRHD (borderline and definitive). Methods: In a prospective cohort study, 1026 children (5–15 years) from disadvantaged areas of São Paulo, Brazil, underwent echocardiographic screening. Participants were classified as normal, borderline SCRHD, or definite SCRHD according to World Health Organization criteria. Plasma levels of interleukin‐6 (IL‐6), tumor necrosis factor‐alpha, and other cytokines were measured at baseline (T0) and after 2 years (T1). Results: The prevalence of SCRHD was 7.6% (95% CI, 6.0%–9.2%), with 6.7% borderline (95% CI, 5.2%–8.2%) and 0.9% as definite (95% CI, 0.3%–1.5%). At baseline, IL‐6 levels were significantly higher in the borderline SCRHD group compared with controls ( P =0.048), while tumor necrosis factor‐alpha showed a trend toward elevation ( P =0.067). No significant differences were observed for interleukin‐2 ( P =0.067), interleukin‐4 ( P =1.000), interleukin‐10 ( P =0.690), interleukin‐17A ( P =0.067), or interferon‐gamma ( P =0.456). Among 44 participants followed for 2 years, IL‐6 and tumor necrosis factor‐alpha levels remained persistently elevated, with no significant change over time ( P =0.626 and P =0.144, respectively), indicating ongoing inflammatory activity. Conclusions: Borderline SCRHD is marked by elevated IL‐6 levels that last for at least 2 years, indicating a sustained proinflammatory state from the earliest detectable stage of the disease. These findings identify interleukin‐6 as a potential early biomarker and therapeutic target to prevent the progression of SCRHD.
- Open Access
- 6 January 2026
- Published by MDPI AG in Preprints.org
Automatic Morphological Evaluation Using Three-Dimensional Transeophageal Echocardiography of Patients with Mitral Prolapse and Insufficiency: Comparison with Patients Without Cardiac Chambers Alterations
Background: There is paucity of information concerning automatic mitral valve apparatus analysis of patients with mitral valve prolapse (MVP). Objectives: We aimed to study with an automatic three-dimensional transesophageal echocardiography (TEE) dedicated software patients with moderate and severe mitral regurgitation when compared to patients with no structural cardiac chamber alterations (patients with patent foramen ovale (PFO) who underwent TEE) . Methods: We employed a TEE software dedicated to automatic analysis of 34 parameters of the mitral valve apparatus comparing MVP patients with moderate and severe mitral regurgitation and patients with PFO without cardiac chamber structural alterations. Mitral valve effective regurgitant orifice (ERO) and regurgitant volume were correlated to automatic MVP parameters. Results: 59 MVP patients and 43 PFO patients were analysed. All MVP patients presented P2 mitral valve prolapse, 15 (25.4 % ) with both posterior and anterior prolapse. Twenty-seven automatic parameters (79%) were different concerning MVP and PFO patients (p< 0.05): diameters, area, perimeter, height, angle, coaptation width, lenght, closure line lenght, annulus. ERO was 0.43 + 0.11 cm2 , and regurgitant volume: 62.2 + 14.9 ml/beat. Automatic analysis correlated to 75 percentile ERO MVP patients (ERO> 0.48 cm2): Posterior Leafltet Area (r:0.74, p:0.031); Posterior Leafltet Lenght (r:0.73, p:0.032); Tenting area (r:0,41, p:0.048). Conclusions: Automatic mitral valve parameters analysis were different concerning MVP and no structural cardiac chamber (PFO) patients. 75 percentile ERO MVP patients (ERO> 0.48 cm2) correlated to posterior leaflet parameters.This anatomic information could be useful to planning and surgical treatment of mitral valve prolapse patients.
- 6 January 2026
- Published by MDPI AG in Preprints.org
Open AccessAutomatic Morphological Evaluation Using Three-Dimensional Transeophageal Echocardiography of Patients with Mitral Prolapse and Insufficiency: Comparison with Patients Without Cardiac Chambers Alterations
Background: There is paucity of information concerning automatic mitral valve apparatus analysis of patients with mitral valve prolapse (MVP). Objectives: We aimed to study with an automatic three-dimensional transesophageal echocardiography (TEE) dedicated software patients with moderate and severe mitral regurgitation when compared to patients with no structural cardiac chamber alterations (patients with patent foramen ovale (PFO) who underwent TEE) . Methods: We employed a TEE software dedicated to automatic analysis of 34 parameters of the mitral valve apparatus comparing MVP patients with moderate and severe mitral regurgitation and patients with PFO without cardiac chamber structural alterations. Mitral valve effective regurgitant orifice (ERO) and regurgitant volume were correlated to automatic MVP parameters. Results: 59 MVP patients and 43 PFO patients were analysed. All MVP patients presented P2 mitral valve prolapse, 15 (25.4 % ) with both posterior and anterior prolapse. Twenty-seven automatic parameters (79%) were different concerning MVP and PFO patients (p< 0.05): diameters, area, perimeter, height, angle, coaptation width, lenght, closure line lenght, annulus. ERO was 0.43 + 0.11 cm2 , and regurgitant volume: 62.2 + 14.9 ml/beat. Automatic analysis correlated to 75 percentile ERO MVP patients (ERO> 0.48 cm2): Posterior Leafltet Area (r:0.74, p:0.031); Posterior Leafltet Lenght (r:0.73, p:0.032); Tenting area (r:0,41, p:0.048). Conclusions: Automatic mitral valve parameters analysis were different concerning MVP and no structural cardiac chamber (PFO) patients. 75 percentile ERO MVP patients (ERO> 0.48 cm2) correlated to posterior leaflet parameters.This anatomic information could be useful to planning and surgical treatment of mitral valve prolapse patients.
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 39 (3)
Posicionamento sobre o Uso do Ultrassom Point-of-Care (POCUS) na Medicina Cardiovascular – 2026: Sumário Executivo
Resumo O ultrassom point-of-care (POCUS) representa uma das mais relevantes inovações na prática clínica cardiovascular contemporânea, funcionando como extensão do exame físico à beira do leito. Este sumário executivo sintetiza o Posicionamento do Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia (DIC-SBC) publicado em 2026, abordando os principais domínios de aplicação do POCUS cardiovascular: avaliação cardíaca, ultrassonografia pulmonar (USP), avaliação da congestão venosa sistêmica (VExUS), pesquisa de trombose venosa profunda (TVP), abordagem do choque circulatório, suporte circulatório mecânico de curto prazo, aplicações na emergência, parada cardiorrespiratória e procedimentos guiados por ultrassom. São apresentados os conceitos fundamentais de treinamento, certificação e os aspectos ético-legais relevantes ao contexto brasileiro. O documento enfatiza que o POCUS não substitui o ecocardiograma diagnóstico completo, mas agrega valor clínico substancial quando aplicado por profissionais devidamente treinados dentro de protocolos estruturados.
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 39 (3)
Open AccessPosicionamento sobre o Uso do Ultrassom Point-of-Care (POCUS) na Medicina Cardiovascular – 2026: Sumário Executivo
Resumo O ultrassom point-of-care (POCUS) representa uma das mais relevantes inovações na prática clínica cardiovascular contemporânea, funcionando como extensão do exame físico à beira do leito. Este sumário executivo sintetiza o Posicionamento do Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia (DIC-SBC) publicado em 2026, abordando os principais domínios de aplicação do POCUS cardiovascular: avaliação cardíaca, ultrassonografia pulmonar (USP), avaliação da congestão venosa sistêmica (VExUS), pesquisa de trombose venosa profunda (TVP), abordagem do choque circulatório, suporte circulatório mecânico de curto prazo, aplicações na emergência, parada cardiorrespiratória e procedimentos guiados por ultrassom. São apresentados os conceitos fundamentais de treinamento, certificação e os aspectos ético-legais relevantes ao contexto brasileiro. O documento enfatiza que o POCUS não substitui o ecocardiograma diagnóstico completo, mas agrega valor clínico substancial quando aplicado por profissionais devidamente treinados dentro de protocolos estruturados.
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 39 (3)
Position Statement on the Use of Point-of-Care Ultrasound in Cardiovascular Medicine – 2026: Executive Summary
Point-of-care ultrasound (POCUS) is one of the most significant innovations in contemporary cardiovascular clinical practice, serving as an extension of the bedside physical examination. This executive summary outlines the Position Statement from the Department of Cardiovascular Imaging of the Brazilian Society of Cardiology (DIC-SBC), published in 2026, covering the key domains of cardiovascular POCUS application: cardiac assessment, lung ultrasound, assessment of systemic venous congestion (VExUS), screening for deep vein thrombosis, management of circulatory shock, short-term mechanical circulatory support, emergency medicine applications, cardiorespiratory arrest, and ultrasound-guided procedures. Fundamental concepts regarding training, certification, and ethical and legal aspects relevant to the Brazilian context are discussed. This document emphasizes that POCUS does not replace a comprehensive diagnostic echocardiogram, but rather adds substantial clinical value when performed by properly trained professionals within structured protocols.
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 39 (3)
Open AccessPosition Statement on the Use of Point-of-Care Ultrasound in Cardiovascular Medicine – 2026: Executive Summary
Point-of-care ultrasound (POCUS) is one of the most significant innovations in contemporary cardiovascular clinical practice, serving as an extension of the bedside physical examination. This executive summary outlines the Position Statement from the Department of Cardiovascular Imaging of the Brazilian Society of Cardiology (DIC-SBC), published in 2026, covering the key domains of cardiovascular POCUS application: cardiac assessment, lung ultrasound, assessment of systemic venous congestion (VExUS), screening for deep vein thrombosis, management of circulatory shock, short-term mechanical circulatory support, emergency medicine applications, cardiorespiratory arrest, and ultrasound-guided procedures. Fundamental concepts regarding training, certification, and ethical and legal aspects relevant to the Brazilian context are discussed. This document emphasizes that POCUS does not replace a comprehensive diagnostic echocardiogram, but rather adds substantial clinical value when performed by properly trained professionals within structured protocols.
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (4)
Diretriz sobre Ecocardiografia de Estresse – 2026
Sumário […] Diretriz sobre Ecocardiografia de Estresse – 2026 Sumário […] Diretriz sobre Ecocardiografia de Estresse – 2026
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (4)
Open AccessDiretriz sobre Ecocardiografia de Estresse – 2026
Sumário […] Diretriz sobre Ecocardiografia de Estresse – 2026 Sumário […] Diretriz sobre Ecocardiografia de Estresse – 2026
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (4)
Guideline on Stress Echocardiography – 2026
Table of contents […] Guideline on Stress Echocardiography – 2026 Table of contents […] Guideline on Stress Echocardiography – 2026
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (4)
Open AccessGuideline on Stress Echocardiography – 2026
Table of contents […] Guideline on Stress Echocardiography – 2026 Table of contents […] Guideline on Stress Echocardiography – 2026
- Open Access
- 3 October 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eRC1568
Platypnea-orthodeoxia syndrome: echocardiography-guided percutaneous treatment
Platypnea-orthodeoxia syndrome, first described in 1949, is a rare clinical condition characterized by positional dyspnea and oxygen desaturation in the upright position that improves when lying down. Herein, we report the case of an 86-year-old patient who experienced episodes of dyspnea on assuming an upright position, which limited her daily activities. The patient’s oxygen saturation was 82% in the standing position and 91% in the supine position. During diagnostic investigation, a patent foramen ovale was identified using transesophageal echocardiography.
- 3 October 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eRC1568
Open AccessPlatypnea-orthodeoxia syndrome: echocardiography-guided percutaneous treatment
Platypnea-orthodeoxia syndrome, first described in 1949, is a rare clinical condition characterized by positional dyspnea and oxygen desaturation in the upright position that improves when lying down. Herein, we report the case of an 86-year-old patient who experienced episodes of dyspnea on assuming an upright position, which limited her daily activities. The patient’s oxygen saturation was 82% in the standing position and 91% in the supine position. During diagnostic investigation, a patent foramen ovale was identified using transesophageal echocardiography.
- Open Access
- 15 May 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 38 (2)
Impacto da Ansiedade em Pacientes Referendados ao Ecocardiograma Transesofágico
Fundamento: A ansiedade é um fator importante para experiência do paciente durante procedimentos médicos. O ecocardiograma transesofágico (ETE) é um exame que necessita sedação, podendo exacerbar a ansiedade e influenciar sua prática. Objetivo Verificar variáveis que influenciam o grau de ansiedade experienciado por pacientes submetidos ao ETE e sua correlação com a sedação. Metodologia Avaliamos pacientes encaminhados para ETE, de ambos os sexos e idade > 18 anos. Foi administrado um questionário de ansiedade (nenhuma, leve, moderada e alta) e coletados dados demográficos, clínicos e fisiológicos. Para efeito de comparação, os pacientes foram divididos em dois grupos: sem ansiedade/ansiedade leve e ansiedade moderada/severa. Resultados Estudamos 63 pacientes, 41 (66%) do sexo masculino, a maioria brancos (87,3%), com idade de 52,5 ± 14,7 anos. Somente 35% dos pacientes apresentavam comorbidades, sendo a mais frequente hipertensão arterial (63,6%), e 70% dos pacientes realizavam o ETE pela primeira vez. A principal indicação para sua realização foi valvopatia (30%). A maior parte dos pacientes (62%) apresentava algum grau de ansiedade: 25 (40%) apresentavam ansiedade leve, 10 (16%) moderada e 4 (6%) de alto grau. Pacientes com ansiedade moderada/severa (p = 0,03) e pacientes mais jovens (p = 0,001) necessitaram maior dose de midazolam para sedação. Conclusão A ansiedade em pacientes referendados para ETE é comum e parece ser menos influenciada por variáveis clínicas. Porém, concluiu-se que pacientes mais ansiosos e mais jovens necessitam de maior quantidade de sedação.
- 15 May 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 38 (2)
Open AccessImpacto da Ansiedade em Pacientes Referendados ao Ecocardiograma Transesofágico
Fundamento: A ansiedade é um fator importante para experiência do paciente durante procedimentos médicos. O ecocardiograma transesofágico (ETE) é um exame que necessita sedação, podendo exacerbar a ansiedade e influenciar sua prática. Objetivo Verificar variáveis que influenciam o grau de ansiedade experienciado por pacientes submetidos ao ETE e sua correlação com a sedação. Metodologia Avaliamos pacientes encaminhados para ETE, de ambos os sexos e idade > 18 anos. Foi administrado um questionário de ansiedade (nenhuma, leve, moderada e alta) e coletados dados demográficos, clínicos e fisiológicos. Para efeito de comparação, os pacientes foram divididos em dois grupos: sem ansiedade/ansiedade leve e ansiedade moderada/severa. Resultados Estudamos 63 pacientes, 41 (66%) do sexo masculino, a maioria brancos (87,3%), com idade de 52,5 ± 14,7 anos. Somente 35% dos pacientes apresentavam comorbidades, sendo a mais frequente hipertensão arterial (63,6%), e 70% dos pacientes realizavam o ETE pela primeira vez. A principal indicação para sua realização foi valvopatia (30%). A maior parte dos pacientes (62%) apresentava algum grau de ansiedade: 25 (40%) apresentavam ansiedade leve, 10 (16%) moderada e 4 (6%) de alto grau. Pacientes com ansiedade moderada/severa (p = 0,03) e pacientes mais jovens (p = 0,001) necessitaram maior dose de midazolam para sedação. Conclusão A ansiedade em pacientes referendados para ETE é comum e parece ser menos influenciada por variáveis clínicas. Porém, concluiu-se que pacientes mais ansiosos e mais jovens necessitam de maior quantidade de sedação.